Negative / Null Result ReportOpen accessMedicine· cited by 43

Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein

Anna C. Navis; Sanne A. M. van Lith; Sander M. J. van Duijnhoven; Maaike de Pooter; Bahar Yetkin-Arik; Pieter Wesseling; Wiljan Hendriks; Hanka Venselaar · 2015 · Acta Neuropathologica

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

MET has gained interest as a therapeutic target for a number of malignancies because of its involvement in tumorigenesis, invasion and metastasis. At present, a number of inhibitors, both antibodies against MET or its ligand hepatocyte growth factor, and small molecule MET tyrosine kinase inhibitors are in clinical trials. We here describe a novel variant of MET that is expressed in 6% of high-grade gliomas. Characterization of this mutation in a glioma cell line revealed that it consists of an intronic deletion, resulting in a splice event connecting an intact splice donor site in exon 6 with

Abstract by Anna C. Navis; Sanne A. M. van Lith; Sander M. J. van Duijnhoven; Maaike de Pooter; Bahar Yetkin-Arik; Pieter Wesseling; Wiljan Hendriks; Hanka Venselaar, Acta Neuropathologica (2015) — licensed CC BY 4.0.

Read the full paper (open access)